• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Nasdaq Gains Over 50 Points; US Durable Goods Orders Rise In February

    3/26/24 10:09:37 AM ET
    $APCX
    $CISS
    $NBSE
    $OPGN
    Computer Software: Prepackaged Software
    Technology
    Marine Transportation
    Consumer Discretionary
    Get the next $APCX alert in real time by email

    U.S. stocks traded higher this morning, with the Nasdaq Composite gaining over 50 points on Tuesday.

    The Dow traded up 0.08% to 39,346.40 while the NASDAQ rose 0.39% to 16,448.92. The S&P 500 also fell, dropping, 0.23% to 5,230.19.

    Check This Out: Top 3 Energy Stocks That May Keep You Up At Night In Q1

     

    Leading and Lagging Sectors

     

    Consumer discretionary shares jumped by 0.7% on Monday.

    In trading on Monday, energy shares fell by 0.2%.

     

    Top Headline

     

    U.S. durable goods orders increased by 1.4% month-over-month in February versus a revised 6.9% decline in January.

     

    Equities Trading UP

     

    Stoke Therapeutics, Inc. (NASDAQ:STOK) shares shot up 74% to $11.31 after the company announced Phase 1/2a data supporting the potential for STK-001 in Dravet syndrome.

    Shares of C3is Inc. (NASDAQ:CISS) got a boost, surging 67% to $0.0587 after the company reported a year-over-year increase in fourth-quarter financial results.

    OpGen, Inc. (NASDAQ:OPGN) shares were also up, gaining 48% to $0.7021 after the company entered into a securities purchase agreement with a private investor, David Lazar, to acquire 3 million shares of Series E Convertible Preferred Stock at $1.00 per share for aggregate gross proceeds of $3.0 million.

     

    Equities Trading DOWN

     

    NeuBase Therapeutics, Inc. (NASDAQ:NBSE) shares dropped 48% to $0.5152 after declining around 3% on Monday.

    Shares of Quhuo Limited (NASDAQ:QH) were down 46% to $0.68.

    AppTech Payments Corp. (NASDAQ:APCX) was down, falling 40% to $0.99 after the company priced its 2 million share offering at $1 per share.

    Also Check This Out: Wall Street's Most Accurate Analysts Say Buy These 3 Energy Stocks With Over 5% Dividend Yields

     

    Commodities

     

    In commodity news, oil traded up 1.7% to $81.98 while gold traded up 0.9% at $ 2,196.70.

    Silver traded up 0.4% to $24.98 on Monday, while copper fell 0.1% to $4.0145.

     

    Euro zone

     

    European shares were higher today. The eurozone’s STOXX 600 rose 0.2%, London’s FTSE 100 rose 0.1% while Spain’s IBEX 35 Index rose 0.3% The German DAX rose 0.7% French CAC 40 rose 0.2% while Italy’s FTSE MIB Index rose 0.3%.

    The GfK Consumer Climate Indicator for Germany rose to -27.4 heading into April compared to a revised reading of -28.8 in the prior period. Spanish economy grew 0.6% in the fourth quarter, compared to a 0.4% increase in the prior period.

     

    Asia Pacific Markets

     

    Asian markets closed mixed on Tuesday, with Japan’s Nikkei 225 falling 0.04%, Hong Kong’s Hang Seng Index gaining 0.88%, China’s Shanghai Composite Index gaining 0.17% and India’s S&P BSE Sensex falling 0.50%.

    Hong Kong’s trade deficit narrowed to $41.7 billion in February versus a $45.4 billion gap recorded in the year-ago period.

     

    Economics

     

    U.S. durable goods orders increased by 1.4% month-over-month in February versus a revised 6.9% decline in January.

    The S&P CoreLogic Case-Shiller 20-city home price index increased by 6.6% year-over-year in January compared to a 6.2% gain in the prior month.

    The FHFA house price index fell by 0.1% in January.

    Now Read This: How To Earn $500 A Month From Micron Technology Stock After Last Week's Strong Earnings

    Get the next $APCX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $APCX
    $CISS
    $NBSE
    $OPGN

    CompanyDatePrice TargetRatingAnalyst
    Stoke Therapeutics Inc.
    $STOK
    2/5/2026$60.00Buy
    Guggenheim
    Stoke Therapeutics Inc.
    $STOK
    1/5/2026$35.00Buy
    Chardan Capital Markets
    Stoke Therapeutics Inc.
    $STOK
    7/18/2025$30.00Buy
    Jefferies
    Stoke Therapeutics Inc.
    $STOK
    12/20/2024$24.00Buy
    Chardan Capital Markets
    Stoke Therapeutics Inc.
    $STOK
    10/14/2024$18.00Outperform
    Leerink Partners
    Stoke Therapeutics Inc.
    $STOK
    3/26/2024Market Perform → Outperform
    TD Cowen
    Stoke Therapeutics Inc.
    $STOK
    11/20/2023Neutral
    JP Morgan
    Stoke Therapeutics Inc.
    $STOK
    7/25/2023Outperform → Market Perform
    TD Cowen
    More analyst ratings

    $APCX
    $CISS
    $NBSE
    $OPGN
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Stoke Therapeutics Inc.

    SCHEDULE 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    2/17/26 4:13:34 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 424B5 filed by Quhuo Limited

    424B5 - QUHUO Ltd (0001781193) (Filer)

    2/11/26 4:31:07 PM ET
    $QH
    Real Estate

    SEC Form 6-K filed by Quhuo Limited

    6-K - QUHUO Ltd (0001781193) (Filer)

    2/11/26 4:30:02 PM ET
    $QH
    Real Estate

    $APCX
    $CISS
    $NBSE
    $OPGN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lord Albert L bought $1,665 worth of shares (4,200 units at $0.40), increasing direct ownership by 0.14% to 3,020,394 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    2/17/26 7:22:57 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Director Lord Albert L bought $52,132 worth of shares (120,000 units at $0.43), increasing direct ownership by 4% to 3,016,194 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    12/4/25 7:22:39 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Director Lord Albert L bought $23,347 worth of shares (57,500 units at $0.41), increasing direct ownership by 2% to 2,896,194 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    11/28/25 5:11:59 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    $APCX
    $CISS
    $NBSE
    $OPGN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    C3is Inc. announces the date for the release of the fourth quarter and twelve months 2025 financial and operating results

    ATHENS, Greece, Feb. 16, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing seaborne transportation services, announced today that it will release its fourth quarter financial results for the period ended December 31, 2025 before the market opens in New York on February 19, 2026. On February 19, 2026 at 10:00 am ET, the company's management will host a conference call to present the results and the company's operations and outlook. Slides and audio webcast: There will also be a live and then archived webcast of the conference call, through the C3is Inc. website (www.c3is.pro). Participants to the live webcast should register on the website

    2/16/26 8:15:00 AM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    Stoke Therapeutics Announces First Patient Dosed in Phase 1 Study of STK-002, a Potential Disease-Modifying Medicine for the Treatment of Autosomal Dominant Optic Atrophy (ADOA)

    –Dose-escalating study will evaluate the safety, tolerability and exposure of STK-002 in people with ADOA– –Changes in visual function, ocular structure and quality of life to be evaluated as secondary objectives– –ADOA is the most common inherited optic nerve disorder and is primarily caused by variants in the OPA1 gene that result in progressive and irreversible vision loss– Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that the first patient has been dosed in the Phase 1 OSPREY study of STK-002, an investigational medicine for the treatment of Autosomal Do

    2/11/26 7:30:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Stoke Therapeutics to Present at the Guggenheim Emerging Outlook: Biotech Summit 2026

    Stoke Therapeutics, Inc. (NASDAQ:STOK) is a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine and has a lead investigational medicine, zorevunersen, in development as a first-in-class potential disease-modifying treatment for Dravet syndrome. Today, the Company announced that Chief Executive Officer Ian F. Smith will present at the Guggenheim Emerging Outlook: Biotech Summit 2026 on Wednesday, February 11, 2026, at 2:30 p.m. ET. A live audio webcast of the presentation, along with an archived replay, will be available in the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Sto

    2/4/26 4:01:00 PM ET
    $BIIB
    $STOK
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Biotechnology: Pharmaceutical Preparations

    $APCX
    $CISS
    $NBSE
    $OPGN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Lord Albert L bought $1,665 worth of shares (4,200 units at $0.40), increasing direct ownership by 0.14% to 3,020,394 units (SEC Form 4)

    4 - AppTech Payments Corp. (0001070050) (Issuer)

    2/17/26 7:22:57 PM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Director Levin Arthur A converted options into 1,211 shares, increasing direct ownership by 33% to 4,842 units (SEC Form 4)

    4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)

    1/5/26 4:16:22 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    New insider Bonte Christian-Laurent claimed ownership of 28,571 shares (SEC Form 3)

    3 - OPGEN INC (0001293818) (Issuer)

    12/10/25 9:08:45 PM ET
    $OPGN
    Medical Specialities
    Health Care

    $APCX
    $CISS
    $NBSE
    $OPGN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Guggenheim initiated coverage on Stoke Therapeutics with a new price target

    Guggenheim initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $60.00

    2/5/26 6:58:02 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chardan Capital Markets resumed coverage on Stoke Therapeutics with a new price target

    Chardan Capital Markets resumed coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $35.00

    1/5/26 9:19:09 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Jefferies initiated coverage on Stoke Therapeutics with a new price target

    Jefferies initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $30.00

    7/18/25 8:16:37 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APCX
    $CISS
    $NBSE
    $OPGN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:58 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Stoke Therapeutics Inc.

    SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 4:24:49 PM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SC 13G/A filed by Stoke Therapeutics Inc.

    SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)

    11/14/24 9:00:12 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APCX
    $CISS
    $NBSE
    $OPGN
    Leadership Updates

    Live Leadership Updates

    View All

    AppTech Payments Corp. CEO and CFO Changes

    CARLSBAD, Calif., Dec. 30, 2024 (GLOBE NEWSWIRE) -- AppTech Payments Corp. ("AppTech or the "Company") (NASDAQ:APCX) announced today that it has accepted the resignation of Luke D'Angelo, as the Company's Chief Executive Officer and Executive Director effective December 24, 2024. Mr. D'Angelo will continue his employment as Chairman of the Company's Board of Directors. The Company has appointed Thomas DeRosa to serve as Interim CEO. "As I step down from my CEO and Executive Director roles, I am filled with immense pride for all we've accomplished together. It has truly been an honor to lead this incredible Company, and I'm grateful to have had the opportunity to work alongside such a tale

    12/30/24 7:45:00 AM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    AppTech Announces $5,000,000 Common Equity Raise and Board Member Changes

    Initial $5 million investment for common stock priced at an average of $0.96 per share; Up to an additional $14 million may be raised from exercise of warrants Albert L. Lord, Thomas J. Kozlowski Jr., and Calvin D. Walsh added to the Board of Directors CARLSBAD, Calif., Dec. 17, 2024 (GLOBE NEWSWIRE) -- AppTech Payments Corp. ("AppTech or the "Company") (NASDAQ:APCX) today announced that AFIOS Partners ("AFIOS"), an investment company including shareholders since 2015, today invested $5 million in the common stock of the Company. In connection with the transaction, the Company reduced its Board to five members from seven and appointed Albert L. Lord, Thomas J. Kozlowski Jr., and Calv

    12/17/24 7:30:00 AM ET
    $APCX
    Computer Software: Prepackaged Software
    Technology

    Stoke Therapeutics Appoints Eric Olson, MS, MBA as Chief Business Officer

    – Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol

    9/4/24 8:00:00 AM ET
    $STOK
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $APCX
    $CISS
    $NBSE
    $OPGN
    Financials

    Live finance-specific insights

    View All

    C3is Inc. announces the date for the release of the fourth quarter and twelve months 2025 financial and operating results

    ATHENS, Greece, Feb. 16, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing seaborne transportation services, announced today that it will release its fourth quarter financial results for the period ended December 31, 2025 before the market opens in New York on February 19, 2026. On February 19, 2026 at 10:00 am ET, the company's management will host a conference call to present the results and the company's operations and outlook. Slides and audio webcast: There will also be a live and then archived webcast of the conference call, through the C3is Inc. website (www.c3is.pro). Participants to the live webcast should register on the website

    2/16/26 8:15:00 AM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    C3is Inc. Announces the Acquisition of Two Medium Range Product Tankers

    ATHENS, Greece, Jan. 22, 2026 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing dry bulk and tanker seaborne transportation services, announced today the expansion of its fleet by entering into two Memoranda of Agreement for the acquisition of two MR product tankers with an approximate capacity of 50,000 dwt per vessel, both built in South Korea in 2008 and 2011, respectively (the "Transaction" or the "Acquisitions"). The purchase price is $16.88 million for the 2008-built tanker and $22.90 million for the 2011-built tanker. The vessels are expected to be delivered to the Company between the first and third quarters of 2026. Following completion

    1/22/26 4:10:00 PM ET
    $CISS
    Marine Transportation
    Consumer Discretionary

    C3is Inc. reports third quarter and nine months 2025 financial and operating results

    ATHENS, Greece, Nov. 18, 2025 (GLOBE NEWSWIRE) -- C3is Inc. (NASDAQ:CISS) (the "Company"), a ship-owning company providing drybulk and tanker seaborne transportation services, announced today its unaudited financial and operating results for the third quarter and nine months ended September 30, 2025. OPERATIONAL AND FINANCIAL HIGHLIGHTS Our handysize dry bulk carriers are on time charters of short-term durations, producing steady cash flows, while our Aframax tanker operates in the spot market, currently achieving voyage charter rates of around $52,000 per day.All of our vessels are unencumbered.Fleet operational utilization of 67.7% for the three months ended September 30, 2025, mainly

    11/18/25 9:00:00 AM ET
    $CISS
    Marine Transportation
    Consumer Discretionary